Skip to content
Screener

Interest Expense at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$63.3M+2,263%
RFL
Rafael Holdings, Inc.RFL
$6K-96.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$1.43M-22.7%
XER
Xeris Biopharma Holdings, Inc.XERS
$6.95M-5.6%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$582K-9.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$840K+18.3%

Segments

By segment

See full
Reportable Segment$0-100%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+12.4%
Enterprise value$561.65M-12.6%
P/E12.1×-225×
P/S5.2×-4.9×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Gain on sale of PRV148,325148,325
Loss on extinguishment of debt(2,756)
Loss on derivative liability(7,216)
Interest expense(2,009)(1,711)(3,978)
Fair value adjustment related to warrant and CVR liability(6,408)(747)(5,440)4,127
Fair value adjustment related to investments(140)(2)(356)(5)
Interest and other income, net2,5652,3786,1552,921
Total other (expense) income(3,983)147,945(11,324)151,390

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s interest expense?
Zevra Therapeutics, Inc. (ZVRA) reported interest expense of $0 in Q2 2026.
How has Zevra Therapeutics, Inc.'s interest expense changed year-over-year?
Zevra Therapeutics, Inc.'s interest expense decreased by 100.0% year-over-year, from $2.01M to $0.
What is the long-term trend for Zevra Therapeutics, Inc.'s interest expense?
Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s interest expense has grown at a 143.7% compound annual growth rate (CAGR), from $226K to $7.98M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Zevra Therapeutics, Inc.'s interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude